JW Pharmaceutical Corporation

KSE 001060.KS

JW Pharmaceutical Corporation EPS (Diluted) for the year ending December 31, 2023: USD 1.10

JW Pharmaceutical Corporation EPS (Diluted) is USD 1.10 for the year ending December 31, 2023, a 9.43% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

JW Pharmaceutical Corporation EPS (Diluted) for the year ending December 31, 2022 was USD 1.00, a 2,025.53% change year over year.
JW Pharmaceutical Corporation EPS (Diluted) for the year ending December 31, 2021 was USD -0.05, a 91.39% change year over year.
JW Pharmaceutical Corporation EPS (Diluted) for the year ending December 31, 2020 was USD -0.60, a 35.66% change year over year.
JW Pharmaceutical Corporation EPS (Diluted) for the year ending December 31, 2019 was USD -0.94, a -451.71% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

KSE: 001060.KS

JW Pharmaceutical Corporation

CEO	Mr. Young-Sub Shin
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	2477, Nambusunhwan-ro
Employees	1,064
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years